Omalizumab has been shown to be an effective add-on therapy for patients with uncontrolled severe persistent allergic (IgE-mediated) asthma. There has been a steady accumulation of evidence on long-term effectiveness of omalizumab; however, data on real-life outcomes beyond one year of treatment in a UK clinical setting is limited. In this analysis, data were compared for a number of patients from the Heartlands Hospital (Birmingham, UK), to determine if improvements were sustained with longer-term treatment. Patients (n = 45, mean age 44.9 years, range: 19–69) received omalizumab for a mean duration of 49.3 months (range: 23–96). All patients with available data (n = 18/45) showed a clinically relevant improvement in asthma control questionnaire (ACQ) scores post-omalizumab (mean ?ACQ: 2.27, range: 0.5–4.1; mean baseline ACQ: 4.1, range: 3.7–4.7). In patients on oral corticosteroids (OCS) vs patients not on OCS (at baseline), improvements were greater: ACQ of patients on OCS at baseline was 4.1 and 1.6 post treatment vs 4.0 at baseline and 2.7 post treatment. Mean OCS dose reduced pre- to post-omalizumab: 30.5 to 7 mg/day. Reductions in hospital admissions/bed days were seen post-treatment (figure). There were also reductions in work/school days missed in 17/19 patients; the other 2 patients showing no change. Overall mean FEV1 was improved in the majority of patients with available data (17/20). Results from this real-life follow-up study demonstrate that improved outcomes in patients with severe allergic asthma are sustained with longer-term omalizumab therapy.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.